Mark Peterson

With a blockbuster Q1 in the rearview, Pebblebrook's upcoming Q2 call is more than a report—it's a referendum on its strategic pivot and the hotel sector's health.

With its third North American acquisition in two years, Axiom GRC isn't just buying a firm—it's buying a strategic foothold in the future of AI governance.

A $20M round for CELYSTRA Pharma isn't just a launch; it's a strategic maneuver to solve Canada's rare disease gap and redefine Québec's role in the market.

The firm is betting that flexibility is the key to unlocking the next wave of SaaS revenue, challenging the rigid models that have defined embedded payments.

New research from Baycrest unmasks paratonia, an involuntary condition often mistaken as defiance, signaling a seismic shift in dementia care and treatment.

Amir Wain's recent Stevie Award isn't just a trophy; it's a validation of a decades-old architectural bet that positions i2c far ahead in the AI race.

A Canadian upstart is poised to unlock a massive, untreated market by moving glaucoma surgery from the OR to the office. This isn't just a new device; it's a strategic dismantling of a decades-old bottleneck.

A new R&D pact between ARCYN Defense and the U.S. Army isn't just a press release; it's a strategic maneuver in the multi-billion dollar C-UAS market.

The 10-year extension for the Las Vegas Grand Prix is more than a race deal; it's a high-stakes maneuver cementing F1's US strategy amid local growing pains.

AM Best affirms Victoria Insurance's 'Good' rating despite a shrinking footprint, revealing a high-stakes balancing act between a fortress balance sheet and immense market risks.

VFF's balance sheet didn't need the cash, so why take it? A deep dive into a strategic capital raise that's less about liquidity and more about legitimacy.

In a move signaling a new era for Chinese healthcare, Fangzhou and Tencent are combining specialized AI with massive tech scale. Is this the blueprint for market dominance?

Julie Mueller's move to acquire 100% of Custom Design Benefits isn't just a transaction; it's a strategic bet on independence in a consolidating market.

Interim Phase 3 data shows Otsuka's VOYXACT not only meets surrogate endpoints but preserves kidney function, a strategic masterstroke in the competitive nephrology market.

A crypto exchange's new campaign is more than a promo; it's a strategic move to merge digital assets with the AI hardware boom. What does this signal?

By expanding its circular carbon black production to China, Orion S.A. is not just opening a new facility; it's executing a global strategy to dominate the next era of tire manufacturing.

In a remote Laotian village, China is field-testing its most strategic export yet: a state-engineered blueprint for poverty eradication. Is this the future of aid?

Canaccord Genuity posts record profits and hikes its dividend, but behind the stellar numbers lies a crucial strategic review of its valuable UK business.

The industrial gas giant's largest-ever membrane facility investment isn't just a local jobs boom; it's a calculated move to dominate the future of energy.

An auto accessory company is launching a new product on two continents simultaneously. This isn't just logistics; it's a signal of the new global EV aftermarket.